Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 229

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 229
---
 of $25,000, (v) up to $3,500 for road
show expenses, and (vi) $15,950 for the clearing expenses.

Also pursuant to the
Engagement Letter, the Company, in connection with the Offering, agreed to issue to the Placement Agent or its designees warrants (the
“Placement Agent Warrants”) to purchase up to an aggregate of 159,468 shares of common stock (the “Placement Agent Warrant
Shares”) (which represents 6.0% of the Shares and Pre-Funded Warrants sold in the Offering). The Placement Agent Warrants will become
exercisable beginning on the effective date of the Warrant Stockholder Approval, have an exercise price of $3.7625 (125% of the combined
public offering price per share of common stock and accompanying Warrants) and will terminate on the five-year anniversary of commencement
of sales in the Offering.

Termination of lease and sale of equipment

On
February 10, 2025, the Company entered into a Bill of Sale and Surrender Agreement (the “Sale/Surrender Agreement”), effective
as of January 31, 2025 (the “Effective Date”), with AbbVie Bioresearch Center Inc., a Delaware corporation (“AbbVie”).
The Company was the tenant in the leased premises located at 377 Plantation Street, Worcester, Massachusetts (the “Premises”)
under a Lease Agreement, dated as of October 27, 2017 (the “Lease”) with WCS - 377 Plantation Street, Inc., a Massachusetts
nonprofit corporation (the “Landlord”). In connection with the entrance into the Sale/Surrender Agreement, the Company also
entered into an Escrow Agreement, dated February 10, 2025 (the “Escrow Agreement”), with Bowditch & Dewey, LLP, as escrow
agent (the “Escrow Agent”), pursuant to which the Escrow Agent would disburse the Purchase Price (defined herein) pursuant
to the terms of the Escrow Agreement.

Pursuant
to the terms of the Sale/Surrender Agreement, AbbVie agreed to purchase from the Company, and the Company agreed to sell and convey to
AbbVie, certain furniture, fixtures and equipment (“FF&E”), which the Company classified as held for sale as of December
31, 2024, located in the Premises and other items as set forth in the Sale/Surrender Agreement